Inversago Pharma Inc
$30,000.00 CAD
≈ 5 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- May 2, 2022 – March 10, 2023
- Reference
- nrc-cnrc:172-2022-2023-Q1-989182
Published purpose
This project will serve to advance Inversago’s CB1 inverse agonist development programs to provide new therapies aimed at improving the lives of patients affected by metabolic and fibrotic conditions.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions